+

WO2001095947A1 - Procede d'evaluation de reponse corticale a la lumiere bleue - Google Patents

Procede d'evaluation de reponse corticale a la lumiere bleue Download PDF

Info

Publication number
WO2001095947A1
WO2001095947A1 PCT/US2001/019083 US0119083W WO0195947A1 WO 2001095947 A1 WO2001095947 A1 WO 2001095947A1 US 0119083 W US0119083 W US 0119083W WO 0195947 A1 WO0195947 A1 WO 0195947A1
Authority
WO
WIPO (PCT)
Prior art keywords
central nervous
nervous system
disorder
blue light
bold
Prior art date
Application number
PCT/US2001/019083
Other languages
English (en)
Inventor
Perry F. Renshaw
Ronald L. Cowan
Blaise De.B. Frederick
Original Assignee
The Mclean Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Mclean Hospital Corporation filed Critical The Mclean Hospital Corporation
Priority to AU2001268414A priority Critical patent/AU2001268414A1/en
Publication of WO2001095947A1 publication Critical patent/WO2001095947A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B24—GRINDING; POLISHING
    • B24B—MACHINES, DEVICES, OR PROCESSES FOR GRINDING OR POLISHING; DRESSING OR CONDITIONING OF ABRADING SURFACES; FEEDING OF GRINDING, POLISHING, OR LAPPING AGENTS
    • B24B49/00—Measuring or gauging equipment for controlling the feed movement of the grinding tool or work; Arrangements of indicating or measuring equipment, e.g. for indicating the start of the grinding operation
    • B24B49/003—Measuring or gauging equipment for controlling the feed movement of the grinding tool or work; Arrangements of indicating or measuring equipment, e.g. for indicating the start of the grinding operation involving acoustic means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence

Definitions

  • This invention relates to central nervous system function.
  • disorders such as Parkinson's disease, attention deficit disorder, schizophrenia, substance abuse, and mood and anxiety disorders generally involve imbalances in central nervous system -functioning, the underlying neurological mechanisms of these diseases are poorly understood, with a corresponding dearth of suitable diagnostic methods and pharmacological therapies.
  • BOLD fMRI Blood oxygen level dependent functional magnetic resonance imaging
  • near infrared optical imaging and emission tomography methods have been used to assess cortical function.
  • the BOLD fMRI method for studying stimulus-induced brain activity changes uses activity-dependent increases in local blood flow, with resultant decreases in the local deoxyhemoglobin concentration as a surrogate marker for increased local neuronal activity, and has been used to analyze visual cortical function.
  • visual stimulus-induced occipital cortical BOLD signal change has been shown to be dependent on gender and age, and to be influenced by disease processes such as schizophrenia.
  • stimulus-induced occipital cortical activation is altered during the administration of exogenous substances, such as amphetamine, cocaine, and ethanol. It would be useful to efficiently diagnose disorders of the central nervous system, and to evaluate effective pharmacological therapies for such disorders.
  • the invention features methods of assessing and diagnosing central nervous system function in a human subject.
  • the invention provides a method of assessing central nervous system function in a human subject by subjecting the subject to a blue light stimulus and performing cortical imaging, for example, functional magnetic resonance imaging, near infrared optical imaging, or emission tomography, on the subject.
  • the method further includes treating the subject with a therapeutic agent for affecting central nervous system dopamine function, to assess the efficacy of the agent.
  • the invention provides a method of diagnosing a central nervous system disorder in a human subject by subjecting the subject to a blue light stimulus and performing cortical imaging, for example, functional magnetic resonance imaging, near infrared optical imaging, or emission tomography, on the subject.
  • the central nervous system disorder includes a disorder of central nervous system dopamine function, e.g., schizophrenia, Parkinson's disease, attention deficit hyperactivity disorder, substance abuse disorders, or mood and anxiety disorders (such as major depression or bipolar disorder).
  • a disorder of central nervous system dopamine function e.g., schizophrenia, Parkinson's disease, attention deficit hyperactivity disorder, substance abuse disorders, or mood and anxiety disorders (such as major depression or bipolar disorder).
  • the blue light stimulus is compared to a light stimulus of a different color (e.g., red or green).
  • central nervous system function is meant any process responsible for, or mediating, affect, mood, behavior, cognition, perception, sensation, brain activity, or motor behavior.
  • central nervous system disorder is meant any disease, pathological condition, or disorder, either acquired or genetically inherited, that adversely affects central nervous system function.
  • blue light stimulus is meant a light stimulus of about wavelength 430-500 nm.
  • red light stimulus is meant a light stimulus of about wavelength 640-700 nm.
  • treating is meant the medical management of a patient with the intent that a cure, amelioration, or prevention of a dependency or a relapse or associated disease, pathological condition, or disorder will result.
  • This term includes active treatment, that is, treatment directed specifically toward i provement of the dependency or associated cure of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the dependency or associated disease, pathological condition, or disorder.
  • this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the dependency, disease, pathological condition, or disorder; preventive treatment, that is, treatment directed to prevention of the dependency or associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the dependency or associated disease, pathological condition, or disorder.
  • treating also includes symptomatic treatment, that is, treatment directed toward constitutional symptoms of the dependency or an associated disease, pathological condition, or disorder.
  • therapeutic agent is meant a compound that is known to, or is proposed to, affect central nervous system neurotransmitter function.
  • a therapeutic agent is one that is used for treating neurologic, psychiatric, or substance abuse disorders.
  • affecting is meant changing, either by decreasing or by increasing.
  • Figure 1A is a graph of BOLD signal increase versus stimulus intensity in Nl for red light in males and females.
  • Figure IB is a graph of BOLD signal increase versus stimulus intensity in Nl for blue light in males and females.
  • Figure 2 is a diagrammatic representation of the -i-amphetamine experimental protocol.
  • Figure 3 is a representative correlation-map display of BOLD signal change through axial oblique sections of visual cortex from a single subject who received drug.
  • Green rectangles represent the Region of Interest (ROI) from right and left Nl, which is placed in maximally activated 1x4 pixel region.
  • the top row is subject response to fixed intensity blue light stimulation over time folio wing ingestion of 2.5 mg -f-amphetamine.
  • the bottom row is same subject showing response to red light in the same experiment.
  • Time post-drug increases from left to right.
  • the calibration bar displays pseudo-color overlay scale as corresponding to correlation coefficient.
  • Figure 4 is a graph of mean activation from right and left Nl from all subjects for blue light stimulation.
  • the Y axis shows the percent signal change from baseline.
  • the X axis shows the trial number.
  • the solid squares represent data from the subjects who received drug, hollow diamonds represent data from
  • Figure 5 is a graph of mean activation from right and left Nl from all subjects for red light stimulation.
  • the Y axis shows the percent signal change from baseline.
  • the X axis shows the trial number.
  • the solid squares represent data from the subjects who received drug, hollow diamonds represent data from the subjects who received placebo.
  • the lines are least squares regression lines.
  • the present invention features methods for assessing central nervous system function and diagnosing central nervous system disorders in a human, and for evaluating therapeutic agents that affect central nervous system neurotransmitter function. Changes in central nervous system neurotransmitter function occur in conjunction with changes in visual system processing, and these visual system changes are linked to alterations in higher brain functions.
  • the invention provides a baseline for average responses, in humans, to red and blue light at varying intensities by using methods for assessing cortical function, for example, functional magnetic resonance imaging (e.g., BOLD fMRI), near infrared optical imaging, or emission tomography, as a non-invasive probe of human neurophysiology. Such methods provide powerful tools to assess intrinsic or exogenously-induced neurotransmitter-specific changes in central nervous system activity.
  • color and frequency responses according to the invention can be used in assays for specific neural system or neurotransmitter system function, for example, for studying dopamine function to diagnose neurologic, psychiatric, substance abuse, or mood and anxiety disorders, or to diagnose any disorder characterized by impaired central nervous system neurotransmitter (e.g., dopamine) function.
  • Blue light response can be compared to those obtained with a light stimulus of a different color, for example, a red or green light stimulus.
  • the response to blue light in comparison with, for example, the response to red light
  • Specific therapeutic agents e.g., neurotransmitter agonist/antagonist medications such as amphetamines
  • neurotransmitter agonist/antagonist medications such as amphetamines
  • the method of the present invention is used to monitor the effects of treatment with therapeutic agents that affect central nervous system neurotransmitter function, and to assess or demonstrate the effects of potential therapeutic agents at specific doses.
  • the BOLD fMRI signal change in occipital cortex, following photic stimulation, is determined by a large number of factors.
  • the known neuronal elements influencing the response are the retina (including photoreceptors, intrinsic neurons, and ganglion cells), the lateral geniculate nucleus (including projections to Nl and intrinsic neurons), and the neurons of Nl (including the layer IN neurons that are the primary targets of the LG ⁇ projection as well as numerous vertical and lateral intrinsic connections).
  • Vascular elements influencing the BOLD signal include the size and number of vessels, their proximity to the region of interest, and degree of coupling between local neuronal activity and blood flow. Hematocrit also influences the BOLD signal.
  • the following examples are provided for the purpose of illustrating the invention and should not be construed as limiting.
  • MRI Magnetic Resonance Imaging
  • MRI scans were performed on a 1.5 Tesla (T) Signa (General Electric, Milwaukee, WI) whole body magnetic resonance image configured with an Instascan (Advanced NMR, Wilmington, MA) whole- body echo planar imaging (EPI) coil.
  • T 1.5 Tesla
  • Signa General Electric, Milwaukee, WI
  • Instascan Advanced NMR, Wilmington, MA
  • EPI whole- body echo planar imaging
  • Structural imaging Anatomical brain structural imaging was performed on each subject in the sagittal, coronal, and oblique planes to provide matched anatomical sections with detail for cross-referencing functional to anatomical images. Using a standard quadrature head coil, Tl volumetric 3D Spoiled Gradient Recall (SPGR) images were obtained with parameters of flip angle 45 degrees, TR 35 mS, TE 5 mS, slice thickness 1.5 mm, field of view (FON) 24x24 cm, matrix size 256 x 256 pixels for an in plane resolution of 0.94 mm.
  • SPGR Transform Gradient Recall
  • BOLD fMRI Functional Analysis Tool
  • FAT Functional Analysis Tool
  • Increased signal intensity in BOLD fMRI images was used as a marker for regional neuronal activation.
  • BOLD signal was analyzed using the statistical mapping method, by applying an automated comparison method to perform a Student's test on a pixel-by-pixel basis of signal during periods defined as baseline or BOLD signal increase.
  • the pixels in a region of interest were used to calculate the magnitude of BOLD signal change.
  • Regions of interest were designed to yield a measure of the zone of best activation within right and left N
  • a 1x4 pixel array oriented with the long axis parallel to the inter-hemispheric fissure was drawn within the region having the best activation according to number or intensity of activated pixels. No regions containing significantly negatively correlated pixel activation were drawn.
  • a region of interest was drawn in a comparable location to activated regions in other slices within Nl.
  • Photic Stimulation Color photic stimulation was delivered via a custom-designed set of stimulus goggles with three independently-controlled sets of light emitting diodes (LEDs) that emit light at 470 nm (blue, Panasonic L ⁇ G992CFBW), 570 nm (green, AND AND183HGP), and 660 nm (red, AND AND180CRP) and can flash independently or in any combination.
  • LEDs light emitting diodes
  • the LEDs and all control electronics were located outside the magnet bore; the goggles were fed by a 20-foor long fiber optic bundle (South Coast Fiber Optics, Alachua, FL). Each eye of the goggles had a 6 row by 8 column matrix of pixels.
  • Each column could be individually controlled to vary intensity and flash patterns (individual eye, individual hemifield, moving vertical bars, etc.).
  • the optical wavelengths were chosen to match the response curves of the three color cones in the human eye; each frequency excites one type of cone preferentially.
  • the threshold detectable BOLD signal increase in response to each color LED was estimated from early data from a few samples, and LED intensity (contrast) was scaled in relation to the threshold. Blue LED intensity was twice that of red LED stimulation. Blue LED intensities ranged from 0.12 lux to 620 lux. Red LED intensities ranged from .06 to 320 lux.
  • goggles permitted the delivery of colored light against a background of essentially complete darkness, however, as the study progressed it was noted that the goggles were not completely light-opaque, introducing the potential for partial illumination of the background via ambient lighting.
  • Ambient room lighting was not controlled and varied according to time of day (light penetrating a skylight) and combination of artificial room lighting (overhead, side, or gantry) lighting. This effect was not quantified but was generally constant within an experimental trial. This problem was corrected in later studies.
  • the baseline activation characteristics of the BOLD fMRI response in the human visual cortex to red and blue light at varying intensities was established by comparing the response to red and blue photic stimuli in a group of healthy control subjects in terms of threshold for activation, slope of the activation response, and hemisphericity of the response.
  • Baseline response parameters were established in a group of controls to enable the application of this technique to the study of individual brain function during the systematic manipulation of central nervous system dopaminergic activity.
  • the analysis was restricted to primary visual cortex rather than higher-order visual areas (including color areas) to develop a method of assessing the synaptic integrity of visual transduction at the earliest stage of neocortical processing.
  • the present invention assesses primary visual cortical activation near threshold and at varying suprathreshold intensities of light, and also compares right and left visual cortical responses.
  • the first experimental series consisted of delivering low-intensity pulses of blue or red light with various LED intensity settings to determine threshold intensity for detectable BOLD activation in Nl .
  • Six male and six female subjects participated and each subject received three different intensities of both red and blue light. Three intensities were delivered in incremental order of intensity for one color, followed by three incremental order intensities in the other color.
  • the choice of the first color order was arbitrary. Blue light intensities were 0.12, 1.2, and 6.2 lux.
  • Blue light was delivered at 4 Hz for 1 subject and at 8 Hz for 11 subjects. Red light intensities were 0.06, 0.32 and 3.2 lux. Red light was delivered at 8 Hz for all subjects. Each trial consisted of 30 seconds on, 30 seconds off, 4 stimulus and 4 rest periods.
  • the intensities were delivered in order of lowest to highest intensity to minimize potential adaptation or response fatigue, and to minimize potential for subject intolerance of prolonged scanner times.
  • a total of 8 (3 female; 5 male) red and 11 (5 female; 6 male) blue light intensity series were performed. Six subjects participated in both the red and blue light stimulation, 8 subjects participated in one or the other but not both.
  • the intensity series were designed so that the lowest intensity was the same as the highest intensity used in the threshold measurements. The higher intensity light data were combined with the lower intensity data from the threshold determinations to determine the best-fit line equation and statistical comparisons.
  • Threshold was defined as the stimulus intensity that would produce statistically significant positive activation in 50% of test subjects. This approach was used to develop an intensity measure that could be used across subjects. The application of this method may be limited by the inability to adjust the stimulus intensity and monitor activation during an experiment (due to the necessity of offline motion correction of images). Applying threshold estimates from preliminary data to the subjects allowed close approximation of the threshold for detectable activation to red light and provided data that allows refinement of the stimulus intensity for determining a more precise threshold for blue light. This approach allows for the application of objective criteria to the response measurement and provides a stimulus intensity-response baseline for comparison during experimental or disease-related alterations. The practical advantages of such an approach are numerous.
  • the mean age for BOLD signal increase in VI was determined by using LED intensities that were at the approximate threshold for detection. Based on preliminary analysis of 3-5 subjects, intensities were targeted so that, at threshold, approximately 50% of the subjects would show a positive BOLD signal increase.
  • the low intensity blue light (0.12 lux) produced positive BOLD signal increase in 11 of 12 (5/6 male, 6/6 female) subjects, while the low intensity red light (0.06) lux produced positive BOLD signal increase in 8 of 12 (4/6 male, 4/6 female) subjects, indicating that the red threshold intensity estimate was closer to the target than that for blue light.
  • Analysis of the near- threshold responses by sex revealed that mean BOLD signal increase was not statistically different for red light, but was significantly lower in females for blue light.
  • Figure 1 is a graph of stimulus intensity versus BOLD signal increase in VI for all nine intensity steps (data are pooled right and left VI from all experiments) for red light ( Figure 1A; intensities were 0.06, 0.65, 3.2, 6.5, 13, 32, 65, 130, and 320 lux) and blue light (Figure IB; intensities were 0.12, 1.2, 6.2, 12, 25, 62, 120, 250, and 620 lux).
  • the abscissa is the logarithmic scale of LED intensity in Lux; the ordinate is percent activation compared to baseline in a 1x4 pixel array from right calcarine cortex. The best-fit trend lines are superimposed.
  • Table 2 Stimulus Intensity BOLD signal response Curve by Sex and Color
  • a human fMRI BOLD study was conducted using alternating red and blue photic stimulation to assess the differential effects of the dopamine-releasing drug -i-amphetamine on the BOLD response in human primary visual cortex. Subjects
  • Exclusion criteria for participation in the study were: 1) cardiovascular illness, 2) current DSM-IV defined (1) Axis 1 psychiatric or substance- related disorder, or history of DSM-IV defined psychotic disorder, 3) current use of psychoactive or vasoactive medications, 4) seizure disorder,
  • Figure 2 is a diagrammatic representation of the photic stimulation and echo-planar imaging (EPI) protocol. Individual time epochs varied more than is illustrated, and actual time measures were used in statistical analyses. The upper portion of the figure depicts the time course of the experiment. Drug or placebo was administered orally at the time defined as 0 minutes. Subjects were then placed in the scanner, goggles were fitted, and baseline structural imaging scans were performed. Echo-planar imaging started at approximately 18 minutes and 5 trials were conducted. The middle of the diagram details a single trial. Within each trial, the start of the BOLD measurement (after discarding 4 dummy scans) was the zero time point. Each BOLD trial lasted 8 minutes 30 seconds, and images were collected at 2 S intervals.
  • EPI echo-planar imaging
  • Red or blue photic stimulation started coincident with the onset of the BOLD trial (color order was varied, red was first in approximately half of all trials).
  • the first four minutes of a trial consisted of a 4-minute epoch of red or blue photic stimulation.
  • Each 4-minute epoch consisted of four 30 S periods of photic stimulation alternating with 4 30 S periods of darkness.
  • An additional 30 S period of darkness was imposed during the color switch portion of the trial, and the 4-minute sequence of photic stimulation alternating with darkness was repeated for the second color.
  • the total inter-scan time was approximately 10 minutes to account for post-imaging processing and storage.
  • MR scans were performed on a 1.5 Tesla (T) Signa Echo-Speed (General Electric, Milwaukee, WI) whole body magnetic resonance scanner (level 5.8).
  • Anatomical brain imaging was performed on each subject in the sagittal, coronal and oblique axial planes to provide matched anatomical sections with detail for cross-referencing functional to anatomical images.
  • Color photic stimulation was delivered via a custom-designed set of stimulus goggles (Frederick B de B et al., 6th Annual Meeting of the Organization for Human Brain Mapping. 2000: San Antonio, TX).
  • the goggles have three sets of light emitting diodes (LEDs) that emit light at 470 nm (blue), 570 nm (green), and 660 nm (red), which can flash independently or in any combination.
  • the optical wavelengths were chosen to match the response curves of the three color cones in the human eye; each frequency exciting one type of cone preferentially (Gouras P and Zrenner E. Vision Research 1981; 21: 1591-1598).
  • the LED 's and all control electronics were located outside of the magnet bore.
  • the goggles were fed by a 20-foot long fiber optic bundle (South Coast Fiber Optics, Alachua FL). Each eye of the goggles had a 6-row by 8-column matrix of pixels.
  • the ROI for this study was chosen in an attempt to study the physiologically most active sub-region (as defined by BOLD signal change) within right and left VI .
  • the anatomical boundaries for VI were determined as follows: The anterior boundary was the parieto-occipital sulcus. The posterior boundary was the occipital pole. The medial boundary was the interhemispheric fissure. The lateral boundary was determined for right and left sides as a maximum of 3 pixel widths lateral to the midline.
  • a 1 x 4 contiguous pixel region whose long dimension was oriented parallel to the interhemispheric fissure was drawn within right VI and left VI to circumscribe a 4 pixel region having the highest correlation coefficient as determined by the correlation map display (see Figure 3 for an example of ROI).
  • the magnitude of BOLD signal increase (activation) was determined as the percent change in the mean signal intensity within the ROI during the period of photic stimulation (average of signal from the 4 stimulation periods for each trial) compared to the mean baseline signal (average of signal from the 4 non-stimulus periods for each trial).
  • a 1x4 pixel ROI was sensitive to small graded changes in BOLD signal within VI.
  • the mean BOLD signal change from the 1x4 ROI in right and left VI was grouped across all trials for the drug and placebo condition to determine if -amphetamine administration altered the mean BOLD signal change.
  • the overall mean was significantly different in the Wald Chi 2 analysis, with the mean BOLD signal change being 28% higher in the drug (2.04%) condition than in the placebo (1.60%) condition (Table
  • the red light elicited BOLD signal there was no effect of time on the red light elicited BOLD signal, but there was a clear time-related peak and decline in blue light evoked BOLD signal over time.
  • the blue light response was more directly influenced by changes in amphetamine-induced dopamine release than was the red light response.
  • the early transient augmentation in VI BOLD signal in response to blue light is likely mediated via a decrease in dopamine release produced by the inhibitory action of dopamine at autoreceptors. As blood levels increase over time, this effect would decay, and would give way to a sustained effect of the higher drug level, likely dominated by increased dopamine release. This idea is consistent with the early onset and transient nature of the blue light response.
  • the hemodynamic effects ofd- amphetamine are constant and common to both colors of light. Therefore, the transient augmentation of the VI BOLD response to blue light is largely neuronal in origin.
  • the sustained augmentation of BOLD signal change reflects hemodynamic, vascular, and neuronal alterations common to both the red and blue light sensory pathways.
  • d- amphetamine produces dose-dependent increases in cardiac output.
  • Peripheral blood pressure increases due to combined changes in cardiac output and increased peripheral resistance via a vasoconstrictive mechanism, which will likely be modest at the doses used in this study.
  • dopaminergic axons (of presumed neuronal origin) directly innervate cerebral microvasculature, and direct application of dopamine to these vessels leads to vasoconstriction.
  • this study demonstrates that very low dose amphetamine produces a general increase in the BOLD response to a fixed stimulus. This effect can be exploited to enhance fMRI signal to detect regional BOLD signal changes that were previously below the level of detectability at baseline for a wide variety of experimental paradigms.
  • the current findings indicate that spontaneously occurring variations in transmitter-specificity among sensory receptors can allow for selective manipulation of transmitter-dependent aspects of a stimulus.
  • the observation of differential dopamine sensitivity for the blue light response indicates that this marker will co-vary with altered dopamine conditions such as schizophrenia, Parkinson's disease, and substance abuse.
  • the present findings further support the use of fMRI in pharmacological assessment of neurophysiology in health and illness. Analysis of both red and blue light responses provides a means to differentiate vascular and neuronal effects of dopaminergic manipulations. Using a volume head coil will also offer the opportunity to assess, for example, the LGN response to amphetamine in parallel with the cortical response. Including drug level measurements in such analyses will further enable diagnosis and therapy of neurotransmitter based functional alterations in humans.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Acoustics & Sound (AREA)
  • Mechanical Engineering (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés permettant d'évaluer la fonction du système nerveux central et de diagnostiquer des affections du système nerveux central chez l'être humain ; et des procédés d'évaluation d'agents thérapeutiques qui agissent sur la fonction des neurotransmetteurs du système nerveux central. L'invention utilise des procédés d'imagerie corticale pour évaluer des modifications dans le traitement du système visuel, et met ces modifications en corrélation avec la fonction du système nerveux central.
PCT/US2001/019083 2000-06-13 2001-06-13 Procede d'evaluation de reponse corticale a la lumiere bleue WO2001095947A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001268414A AU2001268414A1 (en) 2000-06-13 2001-06-13 Method for assessing cortical response to blue light

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21105900P 2000-06-13 2000-06-13
US60/211,059 2000-06-13

Publications (1)

Publication Number Publication Date
WO2001095947A1 true WO2001095947A1 (fr) 2001-12-20

Family

ID=22785434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019083 WO2001095947A1 (fr) 2000-06-13 2001-06-13 Procede d'evaluation de reponse corticale a la lumiere bleue

Country Status (3)

Country Link
US (1) US6630127B2 (fr)
AU (1) AU2001268414A1 (fr)
WO (1) WO2001095947A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229107A1 (en) * 2001-11-02 2003-12-11 Ronald Cowan Magnetic resonance with stimulation
US7010542B2 (en) * 2002-07-20 2006-03-07 Microsoft Corporation Result set formatting and processing
US20050085705A1 (en) * 2003-10-21 2005-04-21 Rao Stephen M. fMRI system for use in detecting neural abnormalities associated with CNS disorders and assessing the staging of such disorders
US20050107682A1 (en) * 2003-10-21 2005-05-19 Rao Stephen M. fMRI system for use in assessing the efficacy of therapies in treating CNS disorders
WO2007143141A2 (fr) * 2006-06-01 2007-12-13 The General Hospital Corporation Procédé d'imagerie optique in vivo comprenant l'analyse d'images dynamiques
US8600696B2 (en) * 2007-09-28 2013-12-03 Oliver Zafiris Method and system for determining a reaction signal for a selected location in an information processing system following the effect of at least one input signal
US10478639B2 (en) * 2011-09-09 2019-11-19 The Regents Of The University Of California In vivo visualization and control of patholigical changes in neural circuits
US9498641B2 (en) * 2012-03-05 2016-11-22 Blue Water Innovations, Llc Fat reducing device and method utilizing optical emitters

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632276A (en) * 1995-01-27 1997-05-27 Eidelberg; David Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same
US5699798A (en) * 1990-08-10 1997-12-23 University Of Washington Method for optically imaging solid tumor tissue
WO1999066830A1 (fr) * 1998-06-24 1999-12-29 Biomax Technologies Inc. Endoscopes et procedes relatifs a une vision directe d'un tissu cible

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5699798A (en) * 1990-08-10 1997-12-23 University Of Washington Method for optically imaging solid tumor tissue
US5632276A (en) * 1995-01-27 1997-05-27 Eidelberg; David Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same
WO1999066830A1 (fr) * 1998-06-24 1999-12-29 Biomax Technologies Inc. Endoscopes et procedes relatifs a une vision directe d'un tissu cible

Also Published As

Publication number Publication date
US20020034472A1 (en) 2002-03-21
AU2001268414A1 (en) 2001-12-24
US6630127B2 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
Lener et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine
Burgmer et al. Altered brain activity during pain processing in fibromyalgia
Satpute et al. Human anterior and posterior hippocampus respond distinctly to state and trait anxiety.
Pugliese et al. The anatomy of extended limbic pathways in Asperger syndrome: a preliminary diffusion tensor imaging tractography study
Hampson et al. Augmented central pain processing in vulvodynia
Barnea-Goraly et al. White matter structure in autism: preliminary evidence from diffusion tensor imaging
Park et al. Blood-oxygenation-level-dependent functional magnetic resonance imaging for evaluating cerebral regions of female sexual arousal response
Zafiris et al. Neural mechanism underlying impaired visual judgement in the dysmetabolic brain: an fMRI study
Cowan et al. Sex differences in response to red and blue light in human primary visual cortex: a bold fMRI study
Schreiber et al. Painful after-sensations in fibromyalgia are linked to catastrophizing and differences in brain response in the medial temporal lobe
Mentis et al. Frequency variation of a pattern-flash visual stimulus during PET differentially activates brain from striate through frontal cortex
Khalili-Mahani et al. Ketamine interactions with biomarkers of stress: a randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men
Hilbert et al. Neurostructural correlates of two subtypes of specific phobia: A voxel-based morphometry study
Cahill et al. MRI-detectable changes in mouse brain structure induced by voluntary exercise
Kullmann et al. Resting-state functional connectivity of the human hypothalamus
EP1272105A2 (fr) Methode et dispositif permettant de mesurer objectivement la douleur, les traitements anti-douleur et autres techniques connexes
Sanganahalli et al. Mitochondrial functional state impacts spontaneous neocortical activity and resting state FMRI
US20030229107A1 (en) Magnetic resonance with stimulation
Olsavsky et al. Neural correlates of taste reward value across eating disorders
Moretti et al. Brain vascular damage of cholinergic pathways and EEG markers in mild cognitive impairment
Park et al. Reduction of ipsilateral thalamic volume in temporal lobe epilepsy with hippocampal sclerosis
US6630127B2 (en) Method for assessing cortical response to blue light
Radoman et al. Neural correlates of predictable and unpredictable threat in internalizing psychopathology
Li et al. Study of the spatial correlation between neuronal activity and BOLD fMRI responses evoked by sensory and channelrhodopsin-2 stimulation in the rat somatosensory cortex
Yasuno et al. Interhemispheric functional disconnection because of abnormal corpus callosum integrity in bipolar disorder type II

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载